Carlos Tajer

Carlos Tajer

Auto-generated profile, based on publicly available information

Carlos Tajer

Hospital El Cruce Nestor Kirchner, Florencio Varela, Provincia de Buenos Aires

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2025 in Global Heart
Verified
Journal Article
Open access
PDF file
ARAndres Rosende
Andres Rosende
CRCesar Romero
Cesar Romero
DDDonald J. DiPette
Donald J. DiPette
JBJeffrey Brettler
Jeffrey Brettler
PSPatrick Van der Stuyft
Patrick Van der Stuyft
POPedro Ordunez
Pedro Ordunez
Background: HEARTS in the Americas is the regional adaptation of the WHO Global HEARTS Initiative, aimed at helping countries enhance hypertension and cardiovascular disease (CVD) risk management in primary care settings. Its core implementation tool, the HEARTS Clinical Pathway, has been adopted by 28 countries. To improve the care of hypertension, diabetes, and chronic kidney disease (CKD), HEARTS 2.0 was developed as a three-phase process to integrate evidence-based interventions into a unified care pathway, ensuring consistency across fragmented guidelines. This paper focuses on Phase 1, highlighting targeted interventions to improve and update the HEARTS Clinical Pathway. Methods: First, the coordinating group defined the project’s scope, objectives, principles, methodological framework, and tools. Second, international experts from different disciplines proposed interventions to enhance the HEARTS Clinical Pathway. Third, the coordinating group harmonized these proposals into unique interventions. Fourth, experts appraised the appropriateness of the proposed interventions on a 1-to-9 scale using the adapted RAND/UCLA Appropriateness Method. Finally, interventions with a median score above 6 were deemed appropriate and selected as candidates to enhance the HEARTS Clinical Pathway. Results: Building on the existing HEARTS Clinical Pathway, 45 unique interventions were selected, including community-based screening, early detection and management of risk factors, lower blood pressure thresholds for diagnosing hypertension in high-CVD-risk patients, reinforcement of single-pill combination therapy, inclusion of sodium-glucose cotransporter-2 inhibitors for patients with diabetes, CKD, or heart failure, expanded roles for non-physician health workers in team-based care, and strengthened clinical documentation, monitoring, and evaluation. Conclusion: HEARTS 2.0 Phase 1 identifies key interventions to integrate and improve hypertension and cardiovascular-kidney-metabolic care within primary care, enabling their seamless incorporation into a unified and effective clinical pathway. This process will inform an update to the HEARTS Clinical Pathway, optimizing resources, reducing care fragmentation, improving care delivery, and advancing health equity, thereby supporting global efforts to combat the leading causes of death and disability.

28 March 2022 in Revista Panamericana de Salud Pública
Verified
Journal Article
Open access
PDF file
POPedro Ordunez
Pedro Ordunez
CTCarlos Tajer
Carlos Tajer
TGThomas Gaziano
Thomas Gaziano
YRYenny A. Rodriguez
Yenny A. Rodriguez
ARAndres Rosende
Andres Rosende
MJMarc G. Jaffe
Marc G. Jaffe
HEARTS in the Americas is the regional adaptation of the World Health Organization’s Global Hearts Initiative, which will be the model for risk management for cardiovascular disease (CVD) in primary health care in the Region of the Americas by 2025. It has already been implemented in 21 countries and 1045 primary health care centers throughout Latin America and the Caribbean. It takes a public health and health systems approach to systematically introduce simplified interventions at the primary health care level and focuses on hypertension as a clinical entry point. This paper introduces a new, improved application (app), the main component of which is the calculator for CVD risk and hypertension management. The paper summarizes the risk assessment approach and the methodology used by the World Health Organization to update its cardiovascular risk charts in 2019; describes the app, its use, functionality and validation process; and provides a set of practical recommendations for optimizing CVD risk and hypertension management by using the app in clinical practice. The HEARTS app is a powerful tool to improve the quality of care provided in primary health settings. The creation and dissemination of the HEARTS app is an essential step in the journey towards eliminating preventable CVD in the Americas.

1 February 2021 in Trials
Verified
Journal Article
Open access
PDF file
JMJavier Mariani
Javier Mariani
CTCarlos Tajer
Carlos Tajer
LALaura Antonietti
Laura Antonietti
FIFelipe Inserra
Felipe Inserra
LFLeon Ferder
Leon Ferder
Walter ManuchaWalter Manucha
Walter Manucha
Objectives: To evaluate whether a single high dose of oral cholecalciferol improves the respiratory outcomes as compared with placebo among adults COVID-19 patients at moderate risk of clinical complications. Trial design: The CARED trial is an investigator-initiated, multicentre, randomized, parallel, two-arm, sequential, double-blind and placebo-controlled clinical trial. It was planned as a pragmatic trial since the inclusion criteria are broad and the study procedures are as simple as possible, in order to be implemented in the routine clinical practice in general wards in the pandemic setting and a middle-income country context. The sequential design involves two stages. The first stage will assess the effects of vitamin D supplementation on blood oxygenation (physiological effects). The second stage will assess the effects on clinical outcomes. Participants: Participants of either gender admitted to general adult wards in 21 hospital sites located in four provinces of Argentina are invited to participate in the study if they meet the following inclusion criteria and none of the exclusion criteria: Inclusion criteria SARS-CoV-2 confirmed infection by RT-PCR; Hospital admission at least 24 hours before; Expected hospitalization in the same site ≥24 hours; Oxygen saturation ≥90% (measured by pulse oximetry) breathing ambient air; Age ≥45 years or at least one of the following conditions: Hypertension; Diabetes; At least moderate COPD or asthma; Cardiovascular disease (history of myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting or valve replacement surgery); Body mass index ≥30; Willingness to sign informed consent (online supplementary material 1 and 2). Exclusion criteria: Age <18 years; Women in childbearing age; >= 72 hs since current admission; Requirement for a high dose of oxygen (>5 litres/minute) or mechanical ventilation (non-invasive or invasive); History of chronic kidney disease requiring haemodialysis or chronic liver failure; Inability for oral intake. Chronic supplementation with pharmacological vitamin D; Current treatment with anticonvulsants; History of: Sarcoidosis; Malabsorption syndrome; Known hypercalcemia or serum calcium >10.5 mg/dL; Life expectancy <6 months; Known allergy to study medication; Any condition at discretion of investigator impeding to understand the study and give informed consent. Intervention and comparator: The intervention consists in a single oral dose of 500.000 IU of commercially available cholecalciferol soft gel capsules (5 capsules of 100.000 IU) or matching placebo Main outcomes: The primary outcome for the first stage is the change in the respiratory Sepsis-related Organ Failure Assessment (SOFAr) score between pre-treatment value and the worst value recorded during the first 7 seven days of hospitalization, the death or discharge, whichever occurs first. The SOFAr score measured as the ratio between the pulse oximetry saturation (SpO2) and FiO2 (27, 28) is used instead of the arterial partial pressure of oxygen (PaO2). SOFAr score is a 4-points scale, with higher values indicating deeper respiratory derangement as follows: 1 PaO2 <400; 2 PaO2 <300; 3 PaO2 <200; 4 PaO2 60 years) and the site. Blinding (masking): Double-blind was achieved by using placebo soft gel capsules with the same organoleptic properties as the active medication. Central management of the medication is carried out by a pharmacist in charge of packaging the study drug in unblinded fashion, who have no contact with on-site investigators. Medication is packaged in opaque white bottles, each containing five soft gel capsules of the active drug or matching placebo, corresponding to complete individual treatment. Treatment codes are kept under the pharmacist responsibility, and all researchers are unaware of them. Numbers to be randomised (sample size): The first stage is planned to include 200 patients (100 per group), the second stage is planned to include 1064 additional patients. The total sample size is 1264 patients. Trial Status: Currently the protocol version is the number 1.4 (from October 13th, 2020). The recruitment is ongoing since August 11th, 2020, and the first subject was enrolled on August 14th. Since then, 21 sites located in four provinces of Argentina were initiated, and 167 patients were recruited by January 11th, 2021. We anticipate to finish the recruitment for the first stage in mid-February, 2021, and in August, 2021 for the second stage. Trial registration: The study protocol is registered in ClinicalTrials.gov (identifier number NCT04411446) on June 2, 2020. Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).

5 January 2016 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Closed access
CTCarlos Tajer
Carlos Tajer
JCJosé Ceresetto
José Ceresetto
FBFederico Jorge Bottaro
Federico Jorge Bottaro
AMAlejandra Martí
Alejandra Martí
MCMarcelo Casey
Marcelo Casey
Oral anticoagulation therapy with vitamin K antagonists (VKA) such as warfarin and acenocoumarol is recommended in patients with atrial fibrillation (AF) and risk factors for embolism. The quality of anticoagulation control with VKA may be assessed by the time in therapeutic range (TTR). In our country, there are no data available about the quality of anticoagulation in patients with AF. The primary goal of our study was to assess the level of effective anticoagulation in a multicenter network of anticoagulation clinics in Argentina, which included patients with nonvalvular AF (NVAF) treated with VKA oral anticoagulants. The TERRA trial is a multicenter, cross-sectional study involving 14 anticoagulation clinics that were invited to participate and recruit 100 consecutive patients with NVAF treated with VKA for more than 1 year. The international normalized ratio (INR) values were retrospectively obtained from patient charts, and TTR was calculated using the Rosendaal method. A total of 1190 patients were included in the analysis. Mean age was 74.9 ± 9.9 years, and 52.5% of the patients were male. Median TTR was 67.5% (interquartile interval 54-80). During 55% of the TTR, INR was >3. Interinstitution variability was substantial, with a range of 57.7% ± 17% to 87.7% ± 17%, P < .001. The 10th percentile of TTR was 41%, the 20th percentile was 50%, the 30th was 58%, and the 35th percentile was 60%. In 40% of patients, TTR was <70%. In this multicenter study, mean TTR values in patients with AF under VKA were similar to those in international therapeutic clinical trials (55%-65%). Marked variations among institutions were observed and, although average results obtained were high, one third of the patients exhibited a TTR below 60%. This cutoff value is conservative according to current recommendations, and guidelines suggest that when management with VKA cannot be improved, patients should be switched to direct oral anticoagulants. The addition of TTR calculation to clinical practice may help improve the quality of oral anticoagulation in patients with AF, thus improving anticoagulation outcomes.

1 January 2017 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
RSRicardo A. Sarmiento
Ricardo A. Sarmiento
RBRodrigo Blanco
Rodrigo Blanco
GGGerardo Gigena
Gerardo Gigena
JLJorge Lax
Jorge Lax
AEAlejandro Garcia Escudero
Alejandro Garcia Escudero
JGJuan A. Gagliardi
Juan A. Gagliardi

4 April 2025 in Revista Argentina de Cardiologia
Verified
Journal Article
Open access
ACAdrián Charask
Adrián Charask
JGJuan Gagliardi
Juan Gagliardi
CTCarlos Tajer
Carlos Tajer
YCYanina Castillo Costa
Yanina Castillo Costa
HDHeraldo D'IMperio
Heraldo D'IMperio
VMVíctor Mauro
Víctor Mauro
Background: Reperfusion treatment is the most effective therapy to reduce ST-segment elevation acute myocardial infarction (STEMI) mortality, and its effectiveness is inversely proportional to total ischemic time. The greatest challenge is to implement its application in real life and continuously correct the deviations or barriers that arise in daily practice. Objectives: The aim of this study was to assess mortality with different reperfusion modalities, their effectiveness and the relations hip of mortality with treatment time. Methods: A national prospective, multicenter study was carried out including patients, with STEMI up to 36 h since symptom onset (ARGEN-IAM-ST continuous registry). Results: A total of 2464 patients from 78 centers were included in the study from 2015 to 2019. In 88.5% of cases, patients received reperfusion treatment. Overall mortality was 8.68%; in patients with reperfusion therapy, mortality was 7.81% vs. 15.38% without reperfusion treatment (p <0.001).Mortality was 7.51% with primary angioplasty, 9.03% with thrombolytics, 2.99% with a pharmacoinvasive strategy and 9.40% with rescue angioplasty, with no statistically significant difference between primary angioplasty and thrombolytics (OR 0.81; 95% CI 0.56-1.18, p = ns).Deceased patients were older and with a higher proportion of women and heart failure. Reperfusion treatment and admission to the institution within 3 hours of symptom onset were associated with lower mortality. Patients with primary angioplasty who died had a longer total ischemic time (378 min vs. 285 min, p <0.001). Conclusions: Mortality from STEMI was associated with access to reperfusion treatment and its early implementation. It was much higher in non-reperfused patients, and lower when reperfusion was carried out early within 3 hours of symptom onset. In patients treated with primary angioplasty, mortality increased with longer total ischemic time. This registry of the actual practice of infarction treatment reinforces the need for a better management of the care system to reduce times and use the best timely strategy. How to cite this article: Charask A. Acute Myocardial Infarction Mortality in Continuous ARGEN-IAM-ST Registry. Its Relationship with Different Reperfusion Therapies. REV ARGENT CARDIOL 2021;89:312-320. http://dx.doi.org/10.7775/rac.v89.i4.20412